 |
Case Report
A durable response to gemcitabine monotherapy in metastatic cardiac angiosarcoma
1 House Officer, Department of Internal Medicine, Henry Ford Health, 2799 West Grand Blvd, Detroit, MI 48202, United States
2 House Officer, Department of Pathology, Henry Ford Health, 2799 West Grand Blvd, Detroit, MI 48202, United States
3 Senior Staff Physician, Department of Hematology/Oncology, Henry Ford Cancer Institute, 2800 West Grand Blvd, Detroit, MI 48202, United States
Address correspondence to:
Matthew Meranda
Department of Internal Medicine, Henry Ford Health, 2799 West Grand Blvd, Detroit, MI 48202,
United States
Message to Corresponding Author
Article ID: 100132Z10MM2024
Access full text article on other devices
Access PDF of article on other devices
How to cite this article
Meranda M, Gokturk-Ozcan G, Girgis M. A durable response to gemcitabine monotherapy in metastatic cardiac angiosarcoma. J Case Rep Images Oncology 2024;10(1):27–30.ABSTRACT
Introduction: Primary cardiac angiosarcoma is a rare neoplasm with high rates of local recurrence and distant metastasis for which optimum treatment is poorly defined.
Case Report: We present the case of a 49-year-old man with cardiac angiosarcoma with distant metastases who exhibits durable response to gemcitabine monotherapy. At initial diagnosis, he underwent complete resection with adjuvant Adriamycin and Ifosfamide for four cycles as well as external beam radiation for possible residual disease. He had recurrence with liver and bone metastases four years later. He received Gemcitabine and Docetaxel for six cycles followed by Gemcitabine monotherapy with no evidence of recurrence for the next three years.
Conclusion: This patient’s consistent response to gemcitabine maintenance therapy in metastatic cardiac angiosarcoma adds to relative paucity of data regarding the management of this rare malignancy, offering insight into best practice and hope for patients afflicted with this disease.
Keywords: Cardiac angiosarcoma, Cardio-oncology, Gemcitabine
SUPPORTING INFORMATION
Author Contributions
Matthew Meranda - Substantial contributions to conception and design, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Gamze Gokturk-Ozcan - Acquisition of data, Revising it critically for important intellectual content, Final approval of the version to be published
Marian Girgis - Substantial contributions to conception and design, Acquisition of data, Interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Guaranter of SubmissionThe corresponding author is the guarantor of submission.
Source of SupportNone
Consent StatementWritten informed consent was obtained from the patient for publication of this article.
Data AvailabilityAll relevant data are within the paper and its Supporting Information files.
Conflict of InterestAuthors declare no conflict of interest.
Copyright© 2024 Matthew Meranda et al.. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.
